Striking a Balance: Exploring the Role of SGLT Inhibitors in the Treatment of Type 1 Diabetes Evaluation (ID: i720a) Question Title * 1. How many patients with diabetes do you manage in your practice? 0 to 10 11 to 20 21 to 30 31 and up Not applicable Question Title * 2. Which of the following best describes the impact of this activity on your performance? I will implement the information in my area of practice. I need more information before I change my practice behavior. This activity will not change my practice, as my current practice is consistent with the information presented. This activity will not change my practice, as I do not agree with the information presented. Question Title * 3. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes Question Title * 4. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 5. What barriers do you see to making changes in your practice? Question Title * 6. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities: Question Title * 7. After participating in today’s activity, I am now able to: Strongly agree Agree Neutral Disagree Strongly disagree Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM Strongly agree Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM Agree Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM Neutral Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM Disagree Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM Strongly disagree Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy Strongly agree Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy Agree Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy Neutral Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy Disagree Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy Strongly disagree Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM Strongly agree Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM Agree Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM Neutral Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM Disagree Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM Strongly disagree Question Title * 8. John Buse, MD, PhD, effectively: Strongly agree Agree Neutral Disagree Strongly disagree Presented the material Presented the material Strongly agree Presented the material Agree Presented the material Neutral Presented the material Disagree Presented the material Strongly disagree Avoided commercial bias Avoided commercial bias Strongly agree Avoided commercial bias Agree Avoided commercial bias Neutral Avoided commercial bias Disagree Avoided commercial bias Strongly disagree Question Title * 9. Anne L. Peters, MD, effectively: Strongly agree Agree Neutral Disagree Strongly disagree Presented the material Presented the material Strongly agree Presented the material Agree Presented the material Neutral Presented the material Disagree Presented the material Strongly disagree Avoided commercial bias Avoided commercial bias Strongly agree Avoided commercial bias Agree Avoided commercial bias Neutral Avoided commercial bias Disagree Avoided commercial bias Strongly disagree Question Title * 10. The content presented: Strongly agree Agree Neutral Disagree Strongly disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly disagree Addressed my most pressing questions Addressed my most pressing questions Strongly agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly disagree Question Title * 11. If you indicated that you perceived commercial bias or influence, please describe: Question Title * 12. How would you rate the format of this activity? Excellent Average Below average Poor Question Title * 13. Would you be willing to participate in a postactivity follow-up survey? Yes No Question Title * 14. Would you like to be contacted about future educational activities in your area of practice? Yes No Done